iBio
iBio's revenue fell 75.0% to $0 million in fiscal 2026. Its operating margin was −35,141.0%, down from −4,650.5% a year earlier. Free cash flow was −$24 million. The diluted share count rose 891.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
iBio lost money in fiscal 2026: a net loss of $33 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 29 | 8 | 14 | 9 | 88 |
| Debt incl. finance leases | 22 | 14 | 1 | — | — |
| Net debt (negative means net cash) | −6 | 6 | −13 | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.3x | 0.9x | 0.1x | — | — |
| Interest coverage | −21.0x | −353.5x | −96.7x | −87.8x | −663.0x |
| Current ratio | 1.5x | 1.2x | 4.1x | 1.6x | 7.8x |
| Quick ratio | 1.4x | 1.2x | 4.1x | 1.6x | 7.8x |
Cash flow
Projections
Project iBio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $98,110 of iBio shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | Marc BanjakChief Legal Officer | Bought | 13,934 | $1.65 | $23,024 | Form 4 |
| Mar 19, 2026 | Felipe DuranChief Financial Officer | Bought | 24,835 | $2.02 | $50,167 | Form 4 |
| Mar 19, 2026 | Martin BrennerSee Remarks, Director | Bought | 12,336 | $2.02 | $24,919 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | 5 of 8 | — | — |
| Rule of 40 | — | −3,752.2% | −23,871.0% |
| Altman Z'' | −33.77 | −49.20 | −2.35 |
| Accruals ratio | −18.2% | −11.8% | −16.1% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 5 of 8 | — | — |
Compare
Put iBio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| iBio | FY26 | −75.0% | −35,141.0% | −23,796.0% | — | — | — | |
| Actinium Pharmaceuticals | FY25 | — | −40,274.4% | −27,426.7% | — | — | — | Compare |
| Avalo Therapeutics | FY25 | −86.6% | −123,601.7% | — | — | — | 2 | Compare |
| Inovio Pharmaceuticals | FY25 | −70.0% | −132,871.3% | −136,074.5% | — | — | 0 | Compare |
| Serina Therapeutics | FY25 | 132.1% | −18,478.5% | −13,856.9% | — | — | 2 | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Revenue growth | −58.4% | 12.7% | 354.5% | −18.8% | 44.8% | −20.5% | −100.0% | — | 77.8% | −75.0% |
| Gross profit | — | — | — | 1 | 1 | 2 | — | — | — | — |
| Research and development | 4 | 4 | 6 | 4 | 10 | 10 | 10 | 5 | 8 | 20 |
| Operating income | −14 | −14 | −16 | −14 | −31 | −30 | −29 | −17 | −19 | −35 |
| Net income | −14 | −16 | −18 | −16 | −23 | −50 | −65 | −25 | −18 | −33 |
| Diluted EPS (US$) | −820.00 | −770.00 | −470.00 | −305.00 | −60.00 | −115.60 | −106.19 | −6.50 | −1.75 | −0.32 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 10 | 104 |
| Cash flow | ||||||||||
| Cash from operations | −13 | −14 | −14 | −13 | −30 | −38 | −30 | −19 | −15 | −23 |
| Capital expenditure | 1 | 1 | 1 | 1 | 5 | 7 | 6 | 0 | 0 | 1 |
| Free cash flow | −14 | −14 | −15 | −14 | −35 | −45 | −36 | −19 | −15 | −24 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 0 | 0 | 2 | 4 | 4 | 2 | 2 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 16 | 4 | 4 | 55 | 77 | 29 | 8 | 14 | 9 | 88 |
| Debt incl. finance leases | — | — | 0 | 33 | 33 | 22 | 14 | 1 | — | — |
| Total assets | 36 | 43 | 31 | 94 | 147 | 99 | 41 | 29 | 23 | 99 |
| Total liabilities | 27 | 27 | 28 | 38 | 38 | 36 | 26 | 7 | 8 | 13 |
| Shareholders' equity | 9 | 16 | 2 | 57 | 109 | 64 | 15 | 21 | 15 | 86 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | 57.1% | 38.3% | 115.0% | — | — | — | — |
| Operating margin | −3,622.8% | −3,204.3% | −782.4% | −854.9% | −1,312.2% | −1,576.3% | — | −7,392.9% | −4,650.5% | −35,141.0% |
| Net margin | −3,688.3% | −3,627.2% | −871.8% | −1,003.6% | −978.8% | −2,670.0% | — | −11,069.8% | −4,594.2% | −33,044.0% |
| Free cash flow margin | −3,676.7% | −3,246.4% | −738.1% | −880.5% | −1,475.5% | −2,378.4% | — | −8,339.6% | −3,830.0% | −23,796.0% |
| Rule of 40 (growth + FCF margin) | −3,735.1% | −3,233.7% | −383.6% | −899.4% | −1,430.8% | −2,399.0% | — | — | −3,752.2% | −23,871.0% |
| Return on capital | — | — | — | −68.2% | −50.0% | −38.8% | −59.1% | −88.2% | — | — |
| Return on equity | −154.2% | −128.4% | −188.9% | −55.6% | −28.1% | −58.5% | −164.9% | −135.7% | −101.5% | −65.7% |
| Return on assets | −33.2% | −40.7% | −47.8% | −26.4% | −19.2% | −40.8% | −92.5% | −71.2% | −70.8% | −54.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |